title: Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB).
abstract: The 11 year disease-free and overall survival for 20 previously untreated patients with Hodgkin's disease stages IIIB (10 patients), IVA (2 patients), and IVB (8 patients) treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin, and bleomycin are presented. The complete response rate was 80% and the median duration of complete remission is 8.6 + years, with a range of 0.5 to 11.0 + years. These results may be better than those obtained with mustine, vincristine, procarbazine, and prednisolone (MOPP) of MOPP alternating with doxorubicin, bleomycin, vinblastine, and docarbazine (ABVD). The results of this small study need to be confirmed by a larger one.
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D013311:Streptozocin / Q000008:administration & dosage / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D013311:Streptozocin; D008130:Lomustine; D004317:Doxorubicin; D011241:Prednisone